[HTML] springer.comFull View

[HTML][HTML] BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

S Khan, J Wiegand, P Zhang, W Hu… - Journal of Hematology & …, 2022 - Springer
KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent
inhibitor of KRASG12C, was recently approved for the treatment of KRASG12C-mutated non …
被引用次数：34 相关文章

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.

S Khan, J Wiegand, P Zhang, W Hu… - … of Hematology & …, 2022 - search.ebscohost.com
KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent
inhibitor of KRAS< sup> G12C, was recently approved for the treatment of KRAS< sup> …

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

S Khan, J Wiegand, P Zhang… - Journal of …, 2022 - mdanderson.elsevierpure.com
KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent
inhibitor of KRAS G12C, was recently approved for the treatment of KRAS G12C-mutated …
[HTML] nih.gov

[HTML][HTML] BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

S Khan, J Wiegand, P Zhang, W Hu… - … of Hematology & …, 2022 - ncbi.nlm.nih.gov
KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent
inhibitor of KRAS G12C, was recently approved for the treatment of KRAS G12C-mutated …

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

S Khan, J Wiegand, P Zhang, W Hu… - … of Hematology and …, 2022 - scholars.uthscsa.edu
KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent
inhibitor of KRAS G12C, was recently approved for the treatment of KRAS G12C-mutated …

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

S Khan, J Wiegand, P Zhang, W Hu… - … of hematology & …, 2022 - pubmed.ncbi.nlm.nih.gov
KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent
inhibitor of KRAS G12C, was recently approved for the treatment of KRAS G12C-mutated …

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.

S Khan, J Wiegand, P Zhang, W Hu… - … of Hematology & …, 2022 - europepmc.org
KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent
inhibitor of KRAS G12C, was recently approved for the treatment of KRAS G12C-mutated …
[HTML] biomedcentral.com

[HTML][HTML] BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

S Khan, J Wiegand, P Zhang… - … of Hematology & …, 2022 - jhoonline.biomedcentral.com
KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent
inhibitor of KRASG12C, was recently approved for the treatment of KRASG12C-mutated non …

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.

S Khan, J Wiegand, P Zhang, W Hu… - … of Hematology & …, 2022 - europepmc.org
KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent
inhibitor of KRAS G12C, was recently approved for the treatment of KRAS G12C-mutated …

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.

S Khan, J Wiegand, P Zhang, W Hu… - … of Hematology & …, 2022 - search.ebscohost.com
KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent
inhibitor of KRAS< sup> G12C, was recently approved for the treatment of KRAS< sup> …